MRNA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MR

Mkt Cap

$86.88B

Volume

20.51M

Next Earnings

November 5th

Loading chart

MR

MRNAModerna, Inc. Common Stock

MRNA

Pay with—

Available Balance0.00

MR

Mkt Cap

$87.04B

Volume

20.51M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer PipelineBioNTech has 16.6 billion euros in cash and is advancing 14 pivotal oncology trials, positioning itself to transition from a COVID-19 vaccine maker to a major cancer treatment company. With a diversified pipeline including promising candidates like pumitamig and a $1 billion share repurchase program, the company has financial flexibility to fund development. However, risks include trial failures, declining COVID-19 revenue, and regulatory delays.The Motley Fool · Oct 17, 2026

The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep GoingThe article examines the six best-performing Nasdaq-100 stocks in 2026, led by Moderna (up 667%), followed by SanDisk, Micron Technology, Marvell Technology, AMD, and Intel. While these stocks have benefited from AI-driven demand and strong fundamentals, the article cautions that their massive gains may already be priced in, making future performance uncertain. Past performance does not guarantee future results, as illustrated by examples like Novo Nordisk, which surged in 2023 but declined in 2024.The Motley Fool · Oct 17, 2026

Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?Moderna stock has surged over 600% in 2026, outperforming major AI stocks like Nvidia, Micron, and Sandisk, driven by progress in its oncology pipeline, particularly its personalized cancer vaccine candidate intismeran autogene. The stock now trades 61% above Wall Street's average price target of $122, and while the company shows promise as it transforms from a coronavirus vaccine company into a broader biotech player, the analyst recommends waiting for a pullback before buying.The Motley Fool · Oct 16, 2026

MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?Moderna's stock gained over 5% in a week, adding $4.2 billion in market value, driven by positive phase III melanoma results for its cancer therapy intismeran and inclusion in the Nasdaq-100 Index. While the company shows promise in oncology and respiratory vaccines, its 625% YTD rally has resulted in a premium valuation that leaves it vulnerable to disappointment. The stock is rated a Hold, with short-term investors advised to book profits while long-term investors may consider holding for future growth opportunities.Zacks Investment Research · Oct 13, 2026

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.The Motley Fool · Oct 13, 2026

Here's Why Moderna (MRNA) Fell More Than Broader MarketModerna (MRNA) declined 5.05% to $213.63 in the latest trading session, underperforming the S&P 500. Despite a 56.28% gain over the past month, the company faces headwinds with projected quarterly EPS of -$1.37 (down 168.63% YoY) and revenue expected at $888.78 million (down 12.52% YoY). The stock holds a Zacks Rank #3 (Hold) rating with consensus EPS estimates revised 0.35% lower in the past month.Zacks Investment Research · Oct 12, 2026

Tempus AI Expands Strategic Collaborations to Drive Future GrowthTempus AI (TEM) is strengthening its precision medicine presence through multiple strategic collaborations, including support for Moderna and Merck's cancer therapy commercialization and an extended data partnership with Recursion Pharmaceuticals through 2029. However, TEM's stock has underperformed the industry by 30.6% over the past year and trades at a premium valuation of 6.73X forward P/S versus the industry average of 4.90X, with the stock currently rated a Hold.Zacks Investment Research · Oct 12, 2026

Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?Moderna stock has surged over 500% this year, driven by investor enthusiasm about its personalized cancer vaccine candidate. The stock now trades 61% above Wall Street's average price target. While the stock may face near-term pullback after its rapid gains, the company's strong pipeline and long-term growth potential in mRNA-based therapies suggest it remains a solid long-term biotech investment, though scaling personalized vaccines presents manufacturing challenges.The Motley Fool · Oct 10, 2026

Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?Moderna (MRNA) will be added to the Nasdaq-100 Index on October 9, replacing Warner Bros. Discovery following its acquisition by Paramount. The inclusion comes after Moderna's 566% year-to-date stock surge and positive phase III results for its personalized cancer therapy developed with Merck. While the index addition could drive incremental institutional demand through index-tracking funds managing over $800 billion in assets, it does not change the company's underlying fundamentals.Zacks Investment Research · Oct 8, 2026

Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now?The article provides an in-depth analysis of the Invesco S&P 500 Equal Weight ETF (RSP), a smart beta ETF with $95.93 billion in assets. RSP uses equal-weighting methodology rather than traditional market cap weighting, with a 0.20% expense ratio and 1.51% dividend yield. The fund has gained 11.2% year-to-date and 12.31% over the past year, with a beta of 0.92. The article compares RSP to alternative cap-weighted ETFs like IVV and VOO, which offer lower expense ratios (0.03%) and potentially lower risk for investors seeking traditional market exposure.Zacks Investment Research · Oct 8, 2026

to start trading

MR

MRNAModerna, Inc. Common Stock

MRNA

Pay with—

Available Balance0.00

Your PositionYou don't own any MRNA yet.

Related Tickers

Earnings